Cowen Initiates Coverage on Gritstone Oncology (GRTS)

Share on StockTwits

Investment analysts at Cowen began coverage on shares of Gritstone Oncology (NASDAQ:GRTS) in a report issued on Tuesday, October 23rd, MarketBeat reports. The brokerage set an “outperform” rating on the stock.

A number of other equities research analysts have also weighed in on GRTS. BTIG Research initiated coverage on Gritstone Oncology in a research note on Tuesday, October 23rd. They set a “buy” rating and a $26.00 price objective for the company. Goldman Sachs Group initiated coverage on Gritstone Oncology in a research note on Tuesday, October 23rd. They set a “neutral” rating and a $18.00 price objective for the company. Finally, Barclays initiated coverage on Gritstone Oncology in a research note on Tuesday, October 23rd. They set an “overweight” rating and a $25.00 price objective for the company.

GRTS stock opened at $23.00 on Tuesday. Gritstone Oncology has a 1 year low of $11.22 and a 1 year high of $27.73.

Gritstone Oncology (NASDAQ:GRTS) last posted its earnings results on Wednesday, November 14th. The company reported ($7.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($6.97). The firm had revenue of $0.10 million during the quarter.

In other news, Director Nicholas Simon bought 333,333 shares of Gritstone Oncology stock in a transaction on Friday, September 28th. The shares were bought at an average price of $15.00 per share, with a total value of $4,999,995.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

A number of large investors have recently added to or reduced their stakes in GRTS. Victory Capital Management Inc. purchased a new stake in Gritstone Oncology in the third quarter valued at approximately $1,424,000. Wells Fargo & Company MN acquired a new position in shares of Gritstone Oncology in the third quarter valued at approximately $578,000. JPMorgan Chase & Co. acquired a new position in shares of Gritstone Oncology in the third quarter valued at approximately $2,065,000. Asymmetry Capital Management L.P. acquired a new position in shares of Gritstone Oncology in the third quarter valued at approximately $285,000. Finally, Alliancebernstein L.P. acquired a new position in shares of Gritstone Oncology in the third quarter valued at approximately $285,000. 0.49% of the stock is currently owned by institutional investors.

Gritstone Oncology Company Profile

Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.

Further Reading: Average Daily Trade Volume – ADTV

Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.